OrSense

Focus: OrSense develops non-invasive blood analyte monitoring devices, primarily focused on hemoglobin measurement technology for hematology applications. The company is based in Raleigh, NC and operates in the medical device/biotechnology space.

Hematology

Profile data last refreshed Yesterday · AI intelligence enriched 1w ago

Open Jobs

About OrSense

AI assessmentNot Hiring

No open roles listed right now. Follow OrSense to get notified when they start hiring — the background below is worth knowing for when they do.

Why Work Here

Data completeness

1/9 — Limited

Company HealthSolid

Pipeline

Early-stage

4 total

LOE Risk

Protected

No near-term cliffs

Hiring

0 open

Automated analysis based on publicly available data (FDA, SEC, ClinicalTrials.gov). May be incomplete or delayed. This score does not reflect insider knowledge and should not be used as the sole basis for investment or employment decisions.

Pipeline & Clinical Trials

A Trial to Evaluate the Precision and Accuracy of the NBM-200 Series When Used in a Continuous Prosp

Anemia

N/A

Clinical Trials (1)

NCT01917487A Trial to Evaluate the Precision and Accuracy of the NBM-200 Series When Used in a Continuous Prospective Mode

N/A

Help build intelligence for OrSense

No one has shared interview or compensation data for this company yet. You'll earn 7 days of Pro access.

Share Interview Share Compensation

Data Sources

Drug label: DailyMed / FDA
Clinical trials: ClinicalTrials.gov
Patent data: FDA Orange Book
Spending data: CMS Medicare

The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.

Early-stage medical device company with 4 active clinical trials demonstrating commitment to validation across multiple indications (hemoglobin H, anemia, obstetric/gynecologic applications)
Opportunity to shape development of non-invasive monitoring technology in underserved hematology market with potential for broad clinical adoption
Ground-floor position at pre-commercialization stage with potential equity upside if technology validation succeeds

Watch Out For

Currently zero open positions and no hiring activity recorded, indicating company is not in active growth or expansion mode
Complete absence of financial, employee count, founding date, and funding data raises transparency concerns and suggests limited public track record or possible early-stage constraints

Generated by Claude from OrSense's SEC filings, pipeline programs, hiring velocity, FDA actions, and WARN data. Inference, not editorial — verify before quoting.

Evaluate the Accuracy of the NBM200 for Noninvasive Hemoglobin Measurements on Obstetric/Gynecologic

Anemia

N/A

Clinical Trials (1)

NCT01917851Evaluate the Accuracy of the NBM200 for Noninvasive Hemoglobin Measurements on Obstetric/Gynecological Patients

N/A

A Clinical Evaluation of the OrSense Non-invasive Blood Hb/Hct Measurement Instrument, the Hemo-Moni

Anemia

N/A

Clinical Trials (1)

NCT01915953A Clinical Evaluation of the OrSense Non-invasive Blood Hb/Hct Measurement Instrument, the Hemo-Monitor NBM200/MP

N/A

NBM-200

Hemoglobin H

N/A

Clinical Trials (1)

NCT05217576NBM-200 Clinical Study in Blood Donation Setting

N/A

Open Jobs (0)

No open positions listed yet. Check their careers page directly.

Interview Prep Quick Facts

Portfolio: 4 clinical trials

Top TAs: Hematology

Pro Feature

Upgrade to Pro to access AI interview prep brief and other premium pharma intelligence.

Upgrade to Pro — $25/mo

Therapeutic Area Focus

Hematology

3 pipeline

Marketed

Pipeline